logo

FDA Calendar

Share SHARE
PDUFA dates and FDA Panel Review dates are very important because they are make or break events for biostocks when the decisions are announced. Also, usually biostocks experience a run-up going into the scheduled decision/review dates. So having prior knowledge of the catalysts goes a long way toward maximizing profit or minimizing loss while trading volatile biotech stocks.

Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.

Get in-depth analysis and insight on investing in the high-stakes biotech and pharma sectors. Check out our
premium biotech research product and our biotech home page.
Company Name
Ticker
Drug
Event
Date
Outcome
Details
Lexicon Pharmaceuticals Inc.
Telotristat Etiprate (NDA)
FDA decision on Telotristat Etiprate for the treatment of carcinoid syndrome
02/28/2017
Clovis Oncology, Inc.
Rucaparib (NDA)
FDA decision on Rucaparib for the treatment of advanced mutant BRCA ovarian cancer.
02/23/2017
Synergy Pharmaceuticals, Inc.
Plecanatide (NDA)
FDA decision on Plecanatide for the treatment of chronic idiopathic constipation
01/29/2017
Biomarin Pharmaceutical Inc.
Brineura (Cerliponase Alfa) (BLA)
FDA decision on Brineura to treat children with CLN2 disease, a form of Batten disease
01/27/2017
FDA decision postponed to Apr.27, 2017
Anacor Pharmaceuticals, Inc.
Crisaborole topical ointment, 2% (NDA)
FDA decision on Crisaborole for treatment of mild-to-moderate atopic dermatitis in children and adults.
01/07/2017
Vericel Corporation
MACI (BLA)
FDA decision on MACI for the treatment of symptomatic cartilage defects of the knee in adult patients
01/03/2017
Cempra, Inc.
Solithera IV (NDA)
FDA decision on Solithera as a treatment for community-acquired bacterial pneumonia
12/28/2016
Roche Holding AG
OCREVUS (BLA)
FDA decision on OCREVUS for the treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis
12/28/2016
Advanced Accelerator Applications S.A.
Lutathera (NDA)
FDA decision on Lutathera for the treatment of gastro entero pancreatic neuroendocrine tumors
12/28/2016
Cempra, Inc.
Solithera oral (NDA)
FDA decision on Solithera as a treatment for community-acquired bacterial pneumonia
12/27/2016
Merck & Co Inc.
KEYTRUDA (sBLA)
FDA decision on KEYTRUDA for 1st line treatment treatment of patients with advanced NSCLC
12/24/2016
Dynavax Technologies Corp
HEPLISAV-B (BLA)
FDA decision on HEPLISAV-B for immunization of adults against hepatitis B infection
12/15/2016
Spectrum Pharmaceuticals Inc
EOquin, now Qapzola (NDA)
FDA decision on Qapzola for the treatment of non-invasive bladder cancer
12/11/2016
Lexicon Pharmaceuticals Inc.
Telotristat Etiprate (NDA)
FDA decision on Telotristat Etiprate for the treatment of carcinoid syndrome
11/30/2016
FDA decision postponed to Feb.28, 2017
Valeant Pharmaceuticals International
VRX, VRX.TO
Brodalumab (BLA)
FDA decision on Brodalumab for treatment of patients with moderate-to-severe plaque psoriasis.
11/16/2016
Pharma-092316.jpg Aradigm Corp.'s (ARDM) two phase III studies of its investigational drug Pulmaquin in patients with non-cystic fibrosis bronchiectasis are proceeding as planned. The top-line data from the two trials are expected to be available in the fourth quarter of this year.
Pharma-Daily-091316.jpg BioMarin Pharmaceutical Inc. intends to seek a review of the Patent Trial and Appeal Board's ruling in the composition of matter patent interference pertaining to exon 51 skipping antisense oligonucleotides, which has gone in favor of Sarepta Therapeutics Inc.
Pharma-092116.jpg Shares of Mast Therapeutics Inc. (MSTX) were down over 83% in extended trading on Tuesday after the company announced that its phase III study of Vepoloxamer in sickle cell disease did not meet the primary efficacy endpoint.
More
The FDA has issued up a warning that some forms of ovarian cancer tests may not be reliable. In a statement the agency has explained that several of the most reliable forms of screening are blood tests, but they may actually create spikes in the very biomarkers they are seeking. "Despite extensive research and published studies, there are currently no screening tests for ovarian cancer . . ."
The rise of e-cigarettes may be increasing the rates at which people are quitting smoking, according to a new study from researchers at the U.K. Center for Tobacco and Alcohol Studies at the University of Nottingham. For the study, the researchers examined the prevalence of smoking in the U.K. between 2014 and 2015 and found as e-cigarettes increased in popularity, more people reported quitting.
As much as 45 toxic chemicals can be found in everyday common house dust, according to a new study. The new study, which saw researchers analyze all studies that have sampled indoor environments in the United States since 2000, found that the chemicals found in dust samples came from a range of things typically found inside your home, including vinyl products, such as flooring and cosmetics.
More
comments powered by Disqus